ATE146483T1 - Peptidische hemmer der hiv-replikation - Google Patents

Peptidische hemmer der hiv-replikation

Info

Publication number
ATE146483T1
ATE146483T1 AT91917865T AT91917865T ATE146483T1 AT E146483 T1 ATE146483 T1 AT E146483T1 AT 91917865 T AT91917865 T AT 91917865T AT 91917865 T AT91917865 T AT 91917865T AT E146483 T1 ATE146483 T1 AT E146483T1
Authority
AT
Austria
Prior art keywords
hiv replication
peptidic inhibitors
peptidic
inhibitors
oligopeptide
Prior art date
Application number
AT91917865T
Other languages
English (en)
Inventor
Martin Sumner-Smith
Richard W Barnett
Lorne S Reid
Nahum Sonenberg
Original Assignee
Allelix Biopharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allelix Biopharma filed Critical Allelix Biopharma
Application granted granted Critical
Publication of ATE146483T1 publication Critical patent/ATE146483T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91917865T 1990-10-24 1991-10-23 Peptidische hemmer der hiv-replikation ATE146483T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60295390A 1990-10-24 1990-10-24

Publications (1)

Publication Number Publication Date
ATE146483T1 true ATE146483T1 (de) 1997-01-15

Family

ID=24413440

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91917865T ATE146483T1 (de) 1990-10-24 1991-10-23 Peptidische hemmer der hiv-replikation

Country Status (11)

Country Link
EP (1) EP0554284B1 (de)
JP (1) JPH06501938A (de)
AT (1) ATE146483T1 (de)
AU (1) AU660947B2 (de)
CA (1) CA2092075A1 (de)
DE (1) DE69123754T2 (de)
DK (1) DK0554284T3 (de)
ES (1) ES2095959T3 (de)
FI (1) FI931801A0 (de)
GR (1) GR3022838T3 (de)
WO (1) WO1992007871A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633230A (en) * 1990-10-24 1997-05-27 Allelix Biopharmaceuticals, Inc. Treatment of cytomegalovirus infection
WO1993021941A1 (en) * 1992-04-23 1993-11-11 Allelix Biopharmaceuticals Inc. Treatment of herpesvirus infection
AU5829994A (en) * 1992-12-22 1994-07-19 Allelix Biopharmaceuticals Inc. Synergistic compositions containing an antiviral nucleoside analogue and an antiviral oligopeptide
US5654398A (en) * 1993-06-03 1997-08-05 The Regents Of The University Of California Compositions and methods for inhibiting replication of human immunodeficiency virus-1
AU685862B2 (en) * 1993-10-22 1998-01-29 Allelix Biopharmaceuticals Inc. Treatment of cytomegalovirus infection
US5627194A (en) * 1993-11-17 1997-05-06 Allelix Biopharmaceuticals Inc. Anti-viral guanidino-substituted compounds
US5441936A (en) * 1993-12-07 1995-08-15 Houghten Pharmaceuticals, Inc. Antiviral peptides
AU6972798A (en) * 1997-04-18 1998-11-13 University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog
IL132941A0 (en) 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US6258774B1 (en) * 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
EP2269654A3 (de) * 1999-08-24 2011-04-13 Cellgate Inc. Verbesserung des Verabreichung von Arzneimitteln durch und in epitheliale Gewebe rch Verwendung von Oligoarginin-Gruppen
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6399067B1 (en) 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
EP2364734B1 (de) 2000-07-21 2017-09-06 ReVance Therapeutics, Inc. Biologische Transportsysteme mit mehreren Komponenten
US7033991B2 (en) 2001-07-16 2006-04-25 Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College Inhibiting furin with polybasic peptides
JP2005525998A (ja) * 2001-08-30 2005-09-02 プラエシス ファーマシューティカルズ インコーポレーテッド 炎症性疾患の治療のための方法および組成物
US8092788B2 (en) 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
ATE461708T1 (de) 2004-05-07 2010-04-15 Univ North Carolina Verfahren zur verstärkung oder hemmung des insulinähnlichen wachstumsfaktors-i
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
CA2597373A1 (en) 2005-02-15 2006-08-24 Thymon, L.L.C. Methods and compositions for impairing multiplication of hiv-1
WO2006094193A2 (en) 2005-03-03 2006-09-08 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of an oligopeptide
ZA200707352B (en) 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP1948230A4 (de) 2005-11-17 2010-03-10 Revance Therapeutics Inc Zusammensetzungen und verfahren zur topischen anwendung und transdermalen abgabe von botulintoxinen mit reduziertem anteil nicht-toxischer proteine
MX2011012875A (es) 2009-06-05 2012-02-28 13Therapeutics Inc Peptidos inmunoreguladores y metodos de uso.
WO2012138879A2 (en) 2011-04-06 2012-10-11 13Therapeutics, Inc. Peptides for the treatment of hearing
CN104768975A (zh) 2012-08-31 2015-07-08 北卡罗来纳大学教堂山分校 用于增强或抑制胰岛素-样生长因子1(igf-1)的单克隆抗体
CN103739674A (zh) * 2013-04-01 2014-04-23 中国人民解放军军事医学科学院野战输血研究所 系列低分子鱼精蛋白模拟肽及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012461A1 (en) * 1988-06-16 1989-12-28 St. Louis University Antagonists of viral transactivating proteins

Also Published As

Publication number Publication date
FI931801L (fi) 1993-04-21
FI931801A7 (fi) 1993-04-21
EP0554284B1 (de) 1996-12-18
AU8725991A (en) 1992-05-26
DE69123754D1 (de) 1997-01-30
GR3022838T3 (en) 1997-06-30
AU660947B2 (en) 1995-07-13
EP0554284A1 (de) 1993-08-11
DK0554284T3 (da) 1997-01-06
ES2095959T3 (es) 1997-03-01
JPH06501938A (ja) 1994-03-03
FI931801A0 (fi) 1993-04-21
WO1992007871A1 (en) 1992-05-14
CA2092075A1 (en) 1992-04-25
DE69123754T2 (de) 1997-04-03

Similar Documents

Publication Publication Date Title
DE69123754D1 (de) Peptidische hemmer der hiv-replikation
TR199801845T2 (xx) Dimerik fibroblast aktifle�tirici protein alfa ve kullan�mlar�.
ES2075040T3 (es) 2',3'-dideoxi-2',2'-difluoronucleosidos.
DK0951473T3 (da) Cyclosporinderivat, fremstilling af dette og farmaceutiske præparater indeholdende dette
DE69326250D1 (de) Neuropeptide y antagoniste
BR9714358A (pt) Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
ATE169822T1 (de) Behandlung von herpesvirus infektion
TR199802079T2 (xx) D-Manitol ve haz�rlanmas�.
DE69636285D1 (de) ISOLIERTES FrpB NUKLEINSÄUREMOLEKÜL UND ENTSPRECHENDE IMPFSTOFF
AP2002002584A0 (en) Protease Inhibitors And Thier Pharmaceutical Uses.
ATE201693T1 (de) Hämoregulierende peptide
PT666919E (pt) Vacina contendo uma protease de tiol
RU94014631A (ru) Производные 4-хиномиодигидропиридина, смесь их изомеров или отдельные изомеры и их соли
ATE184787T1 (de) Therapeutische kombinationen
DE69514928D1 (de) Gegen protozoen wirksamezyklische tetrapeptide
NO931503L (no) Peptidbaserte inhibitorer av hiv-replikasjon
TR200401875T2 (tr) Endoparazit öldürücü bileşimler
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
ES2176363T3 (es) Peptidos de la proteina gag del vih, su preparacion y su uso.
ES2091159A1 (es) Antigeno recombinante, rsm14, procedente de schistosoma mansoni, su obtencion y utilizacion.
SE9702242D0 (sv) Vaccine compositions V
DK0783319T3 (da) Muramylpeptid-sammensætninger til inhibering af HIV replikation
KR970704441A (ko) 사람 면역결핍증 바이러스 프로테아제 억제제 배합물(HIV Protease inhibitor combination)
KR900002787A (ko) 인체 후천성 면역부전증후군 바이러스 감염 저해제

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee